Annotation: The group of non-steroidal anti-inflammatory drugs (NSAIDs) is one of the most popular medications in Russian Federation. The high level of consumption is explained by the wide range of indications for use and wide availability, which in turn leads to uncontrolled and unreasonable use and the development of events associated with issues of pharmacological safety of patients.

Aim: Assessment of the socio-economic burden of adverse drug reactions for non-steroidal anti-inflammatory drugs using the example of the international non-proprietary name (INN): paracetamol

Materials and methods: In this article calculations of the socio-economic burden of the use of NSAIDs are modeled using the example of the  paracetamol. The national database «Pharmacovigilance» was used as a register of adverse drug reactions when paracetamol was used. During assessing the burden, direct medical costs (payment for a completed case of inpatient treatment, stay in the resuscitation and intensive care unit, calling an ambulance), direct non-medical costs (payment of benefits on a disability certificate) were taken into account. The source of information on prices was: compulsory health insurance tariffs, price lists of state and commercial clinics.

Conclusions: Direct medical costs, which included the development of the "best" scenario for pharmacotherapy with paracetamol for the period from 2010 to 2020  amounted to 10,277,410.60 rubles, when calculating the main analysis, the costs of providing adverse drug reactions were 13,108,219.20 rubles, in the framework of the “worst” scenario, the costs amounted to 24,683,842.36 rubles. Thus, the development of the “best” scenario will be 0.13% of the amount initially spent on pharmacotherapy with paracetamol, in the framework of the main analysis - 0.17% and, in the development of the "worst" scenario - 0.32%, which indicates that the use of paracetamol is economically justified.

Syrayeva Gulnara graduated from St. Petersburg State Medical University named after I.I. Pavlova in 2010. Dr. Syrayeva has two specializations - infectious diseases and clinical pharmacology, has published more than 20 articles, she is a speaker at international conferences. In addition, she participates in the organization and conduct of clinical trials.